The use of RNA to deliver ICIs to GI tumors has also been explored by the administration of LNPs containing an mRNA encoding for pembrolizumab (an anti-hPD-1 mAb) in MC38 tumors implanted in an hPD-1 knock-in mouse model [153]. Here, PDCD1 is linked to digestive system neoplasm.